No Data
No Data
Earnings Call Summary | Arcus Biosciences(RCUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arcus Biosciences reported that they have over $1 billion of cash on hand, which
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 87.5% Wedbush → $30 Reiterates Outperform → Outperform 03/25/2024 212.5% Truist Securities → $5
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties